skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

The application of exosomes as a nanoscale cancer vaccine

Review

(7888) Views  (1331) Full article downloads

Authors: Aaron Tan, Hugo De La Peña, Alexander M Seifalian

Published Date November 2010 Volume 2010:5 Pages 889 - 900
DOI: http://dx.doi.org/10.2147/IJN.S13402

Aaron Tan1, Hugo De La Peña2, Alexander M Seifalian1,3
1UCL Division of Surgery and Interventional Science, Centre for Nanotechnology and Regenerative Medicine, University College London, London, UK; 2Department of Pathology, University of Cambridge, Cambridge, UK; 3Royal Free Hampstead NHS Trust Hospital, London, UK

Abstract: Cancer is a leading cause of death globally, and it is predicted and projected to continue rising as life expectancy increases. Although patient survival rates for some forms of cancers are high due to clinical advances in treatment protocols, the search for effective cancer vaccines remains the ultimate Rosetta Stone in oncology. Cervarix®, Gardasil®, and hepatitis B vaccines are currently employed in preventing certain forms of viral cancers. However, they are, strictly speaking, not ‘true’ cancer vaccines as they are prophylactic rather than therapeutic, are only effective against the oncogenic viruses, and do not kill the actual cancer cells. On April 2010, a new prostate cancer vaccine Provenge® (sipuleucel-T) was approved by the US FDA, and it is the first approved therapeutic vaccine that utilizes antigen-presenting cell technology involving dendritic cells in cancer immunotherapy. Recent evidence suggests that the use of nanoscale particles like exosomes in immunotherapy could form a viable basis for the development of novel cancer vaccines, via antigen-presenting cell technology, to prime the immune system to recognize and kill cancer cells. Coupled with nanotechnology, engineered exosomes are emerging as new and novel avenues for cancer vaccine development. Here, we review the current knowledge pertaining to exosome technology in immunotherapy and also seek to address the challenges and future directions associated with it, in hopes of bringing this exciting application a step closer toward an effective clinical reality.

Keywords: exosomes, cancer vaccine, immunotherapy, nanomedicine

 






 

Other articles by Professor Alexander Seifalian



Readers of this article also read:

Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases
Nanomedicine: promises and challenges for the future of public health
Intracellular heavy metal nanoparticle storage: progressive accumulation within lymph nodes with transformation from chronic inflammation to malignancy
Concentration-dependent toxicity of iron oxide nanoparticles mediated by increased oxidative stress
Recent advances in PEG–PLA block copolymer nanoparticles
Cardiovascular application of polyhedral oligomeric silsesquioxane nanomaterials: a glimpse into prospective horizons
Solvent effects on structural and thermochemical properties of p53 tumor-suppressor gene: a molecular modeling approach in drug design
Adhesion of bio-functionalized ultrasound microbubbles to endothelial cells by targeting to vascular cell adhesion molecule-1 under shear flow
A new era of cancer treatment: carbon nanotubes as drug delivery tools
Functionalization of single-walled carbon nanotubes and their binding to cancer cells